信達生物(01801.HK)逆市續漲近一成 擴大與禮來藥物授權許可
信達生物(01801.HK)與禮來達成擴大藥物授權許可協議,該股延續昨天倒升勢,今天升破10天、20天及50天線(49.8元-52元),最高見54.5元,現造54.45元,續漲9.8%,成交增至1,031萬股,涉資5.48億元。
信達生物公布,與禮來製藥達成雙方共同於內地開發的抗PD-1單克隆抗體免疫腫瘤藥物達伯舒的擴大授權許可協議。據此,禮來將獲得達伯舒在內地以外區域獨家許可,並計劃推向美國和其他地區市場。公司將收到2億美元首付款,並有資格獲得高達8.25億美元潛在開發和商業化里程碑付款及雙位數比例的淨銷售額提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.